Goresp Digihaler

Goresp Digihaler is a prescription dry‑powder inhaler that delivers a fixed combination of budesonide and formoterol fumarate dihydrate for inhalation. The device provides an integrated digital component that records inhalation events, supporting adherence monitoring. Budesonide is an inhaled corticosteroid (ICS) and formoterol is a long‑acting β2‑agonist (LABA), together offering anti‑inflammatory and bronchodilator effects for maintenance therapy of asthma and COPD in adult patients and children.

Goresp Digihaler is indicated for long‑term maintenance treatment of respiratory conditions where both anti‑inflammatory and bronchodilator actions are required.

- Maintenance therapy for asthma in patients aged 12 years and older. - Maintenance therapy for chronic obstructive pulmonary disease (COPD) to reduce exacerbations. - As a step‑up option when asthma is not adequately controlled with inhaled corticosteroid alone. - For patients who benefit from a combined inhaled corticosteroid/long‑acting β2‑agonist in a single inhaler. - To improve adherence through digital dose‑tracking capabilities.

The safety profile of Goresp Digihaler reflects the known effects of its corticosteroid and LABA components.

Common: - Throat irritation or soreness, often mild and transient. - Hoarseness or voice changes, especially after repeated use. - Cough, wheeze, or a feeling of tightness in the chest shortly after inhalation. - Oral thrush (candidiasis), which may present as white patches in the mouth. - Headache, tremor, or a sense of nervousness that usually resolves on its own.

Serious: - Paradoxical bronchospasm, a sudden worsening of breathing that may require immediate medical attention. - Suppression of the hypothalamic‑pituitary‑adrenal axis, potentially leading to adrenal insufficiency with prolonged high‑dose use. - Cardiac rhythm disturbances such as tachycardia, palpitations, or arrhythmias, particularly in patients with pre‑existing heart disease.

When prescribing Goresp Digihaler, clinicians should consider several precautionary measures to ensure safe and effective use.

- Assess patient’s asthma or COPD control before initiating therapy and review inhaler technique regularly. - Use the lowest effective dose to achieve symptom control and minimize systemic corticosteroid exposure. - Monitor for signs of oral candidiasis and advise rinsing the mouth after each inhalation. - Evaluate for cardiovascular disease, as formoterol may increase heart rate and cause palpitations. - Consider potential adrenal suppression in patients receiving high‑dose or long‑term corticosteroid therapy. - Avoid use as a rescue medication; it is intended for maintenance treatment only.

Goresp Digihaler may interact with other medicines; awareness of these interactions helps prevent reduced efficacy or increased adverse effects.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that can raise systemic budesonide levels. - Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants that may enhance β‑agonist effects on the heart.

Use with caution: - Other inhaled or oral corticosteroids, which may increase the risk of systemic steroid side effects. - β‑blockers, especially non‑selective agents, which can diminish the bronchodilator response. - Diuretics or digoxin, as formoterol may cause hypokalemia or affect cardiac conduction.